Congress blocks Medicare rule requiring advance approval for services
S.J.Res. 192 — A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model". · Filed by Ron Wyden (D-OR) · 20 cosponsors · Introduced May 19, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This joint resolution uses the Congressional Review Act to block a Medicare rule that would require prior authorization (advance approval) for certain medical services under a pilot program called WISeR, designed to reduce wasteful and inappropriate care. If passed, the rule would be nullified and CMS could not reissue it without new congressional approval.
Why we flagged it
This is a procedural instrument under the Congressional Review Act (5 U.S.C. ch. 8) that nullifies a specific Medicare rule. It does exactly one stated thing: block the WISeR prior authorization rule from taking effect.
What the text implies
- Blocking the rule prevents CMS from implementing the prior authorization pilot across select Medicare services, preserving the status quo of unrestricted service ordering and potentially higher Medicare spending.
- The disapproval does not prevent CMS from issuing a substantially similar rule in the future, but it signals congressional opposition and raises the political cost of resubmission.
- Pharmaceutical and medical device manufacturers (mapped stocks: PFE, JNJ, BMY) benefit from unrestricted access to Medicare reimbursement without prior authorization gatekeeping, as do dialysis providers (DVA) and other service providers subject to the rule.
- Patients who would have benefited from reduced unnecessary procedures and lower out-of-pocket costs lose that protection; conversely, patients facing prior authorization delays are spared that friction.
- The bipartisan sponsorship (20 cosponsors, led by Wyden and Murray, both Democrats) suggests this is not a partisan healthcare fight but reflects provider and industry lobbying across both parties.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The rule aims to reduce unnecessary medical spending by requiring advance approval for select services, potentially lowering costs and preventing harm from inappropriate care. However, prior authorization can delay necessary treatment and shift administrative burden onto patients and providers, creating access barriers. The balance between cost control and care access is genuinely contested.
Who stands to gain
- pharmaceutical manufacturers
- medical device manufacturers
- dialysis providers and other healthcare service providers
- healthcare providers subject to prior authorization requirements
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), WISeR Model (Wasteful and Inappropriate Services Reduction), Congressional Review Act (5 U.S.C. ch. 8), Government Accountability Office (GAO), Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)
Where it stands
20 cosponsors: 19 Democrats, 1 Independents.
- May 19, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- May 19, 2026 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
- Jun 9, 2026 — Reported out of committee · Congress.gov: “Senate Committee on the Judiciary discharged, by petition, pursuant to 5 U.S.C. 802(c)”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $552,230 in lobbying spend. A filing names 93 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Ron Wyden, the sponsor, reported $375,070 in PAC receipts in the 2026 cycle.
- American Federation of Teachers — $410,000 on 1 filing
- National Association of Accountable Care Organizations — $142,230 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,221 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress blocks Medicare rule requiring advance approval for services” QuorumCivic. https://share.quorumcivic.app/bill/119/sjres192 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.